Description

1. Product Overview: AVAPAG® is an oral thrombopoietin receptor agonist containing Avatrombopag, used to increase platelet counts in patients with thrombocytopenia of various causes.

2. Composition: Avatrombopag INN 20 mg | Dosage Form: Tablet

3. Pharmacological Class: Thrombopoietin (TPO) Receptor Agonist

4. Mechanism of Action: Avatrombopag stimulates thrombopoietin receptors on megakaryocyte precursors in the bone marrow, increasing platelet production and improving platelet counts.

5. Indications: Thrombocytopenia in chronic liver disease patients prior to procedures | Immune thrombocytopenia (ITP) | Other conditions associated with low platelet count (as prescribed)

6. Dosage & Administration: As directed by physician or specialist only | Oral use | Usually taken once daily with food | Dose depends on platelet count and clinical condition

7. Clinical Benefits: Increases platelet count | Reduces bleeding risk | Helps avoid platelet transfusion in selected cases | Supports safe medical procedures

8. Contraindications: Hypersensitivity to Avatrombopag or any component of the formulation

9. Precautions: Risk of thromboembolic events | Regular platelet monitoring required | Use cautiously in patients with clotting risk factors

10. Drug Interactions: May interact with OATP1B1/1B3 inhibitors and other drugs affecting hepatic transport

11. Special Populations: Use in pregnancy and lactation only if clearly necessary and prescribed | Pediatric use under specialist supervision

12. Adverse Effects: Headache | Fatigue | Nausea | Abdominal discomfort | Increased risk of thrombosis (rare)

13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children

14. Packaging: Tablet blister pack

15. Manufacturer: Everest Pharmaceutical Ltd.